All News

US Census data show the segment of the population over age 65 is growing faster than the group under age 65, highlighting the need for new healthcare delivery solutions.

clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.

Truvada and Descovy are both manufactured by Gilead Sciences and used to treat HIV-1 infection and as pre-exposure prophylaxis (PrEP) in adult and pediatric patients.

Accountable care organization (ACO) participation in the Medicare Shared Savings Program (MSSP) remained flat this year, according to a press release from the National Association of Accountable Care Organizations issued Friday, January 10.

The operative times of third-year residents learning phacoemulsification may be significantly reduced by early and continuous implementation of mandatory virtual simulator surgical training before starting to perform intraocular surgery, according to a recent study.

Avalere Health broadcasted its annual Healthcare Industry Outlook for 2020 on January 9. The hour-long discussion included insights on some of the top healthcare topics predicted to have an impact in 2020. Although Medicare and drug pricing took center stage, artificial intelligence, the future of the Affordable Care Act, and 2020 presidential campaign platforms were among the subjects discussed.

It's time for curated, customer-centric thinking to come to healthcare, writes healthcare industry executives.

The Trump administration has indicated that the Supreme Court should wait to take up a case on the Affordable Care Act (ACA); a Chinese pneumonia outbreak claimed the life of one victim; this year’s flu strain is hitting children the hardest.

Narcolepsy type 1 (NT1) may be caused by an autoimmune T-cell response to orexins and could be triggered by flu antigens, according to study findings.

The Center for Biosimilars, a sister site of The American Journal of Managed Care® (AJMC®), reports on the most controversial topics in the biosimilars industry in 2019.

Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.

For those with mild to moderate chronic obstructive pulmonary disease (COPD), researchers suggest that antibiotic stewardship focus on reducing and optimizing antibiotic use in patients with severe COPD who have a significant risk of drug resistance, according to study findings.

Nigeria has a population of almost 204 million. Of those, 3.1% of adults, or 3.5 million, are living with HIV. The accompanying death anxiety of people living with HIV and AIDS has not been studied in depth.

The biosimilar candidate treats paroxysmal nocturnal hemoglobinuria, a rare blood condition that features destruction of red blood cells, thrombosis, and impaired bone marrow function.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation occurs in close to 6% of patients with gastrointestinal stromal tumors (GIST), the most common being the D842V mutation, for which there is no effective, approved treatment. The drug previously received breakthrough therapy, fast track, and orphan drug designations.

California is looking to launch a generic drug label; workplace suicides are on the rise; multisensory stimulation therapy could help those with OCD.

The authors calculate that Medicaid expansion saved up to 8100 lives between 2014 and 2016, as the Affordable Care Act (ACA) took full effect.

This week, the top managed care stories included cancer deaths falling for the 25th straight year; a study finding no link between talc powder and ovarian cancer; a poll finding 1 in 4 patients with Parkinson disease may be misdiagnosed.

Hospitalizations due to heart failure (HF) were associated with a risk for kidney failure (KF) that was 11.4-times greater compared with patients who did not have cardiovascular disease (CVD). Among a group of CVDs that also included atrial fibrillation, coronary heart disease, and stroke, HF was associated with the highest risk of developing subsequent KF.

A new coronavirus may be to blame for a pneumonia outbreak in China; costs to give birth increase, even with employer coverage; HHS declares a public health emergency in Puerto Rico after a devasting earthquake.

Priority review was based on phase 3 results from DAPA-HF, presented in Paris at the European Society of Cardiology and published in the New England Journal of Medicine.

While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.

This week, the FDA’s Center for Drug Evaluation and Research (CDER) released its annual report, Advancing Health Through Innovation: New Drug Therapy Approvals, outlining new drugs approved or marketed in America for the first time.

Most residents of Kansas face surprise out-of-network medical bills; drugstore chains fight back in the ongoing opioid epidemic; young adults face a greater stroke risk if they use both e-cigarettes and cigarettes.

The use of interferon-beta (IFN-beta) by pregnant patients with multiple sclerosis poses no risk to an infant’s birth weight, length, or head circumference, according to a recent study.

The overall cancer death rate declined by 29% from 1991 to 2017, with a 2.2% decline from 2016 to 2017 serving as the largest single-year drop in reported cancer mortality, according to research published today; however, obesity-related cancer deaths are rising and prostate cancer deaths remain stagnant.

In the first clinical trial of its kind, Danish researchers investigated the efficacy of a combination treatment of ruxolitinib and low-dose pegylated interferon-α2 (PEG-INF α2) in patients with polycythemia vera and myelofibrosis, according to a study published in Haematologica.